Dr Kiran Mazumdar-Shaw, CMD, Biocon (Photo Courtesy: www.luxpresso.com)
The acquisition is said to be effective from October 1, 2015.
The unit is involved in manufacturing advanced intermediates of potent APIs (Active Pharmaceutical Ingredients).
The financials of the transaction were undisclosed.
According to Biocon, the facility measures 45,000 sq ft, and spread across 7 acres.
The manufacturing facility's production areas is divided into Block I and Block II, measuring 22,600 sq ft and 22,065 sq ft respectively.